Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

35.63 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	93
Open	35.63
Bid (Size)	35.13 (100)
Ask (Size)	35.86 (100)
Prev. Close	35.63
Today's Range	35.63 - 35.63
52wk Range	18.92 - 43.15
Shares Outstanding	99,581,693
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Here's Why Viking Therapeutics Stock Recovered and Can Soar 2026 ↗

March 11, 2026

The company is pursuing a Phase 3 trial in its most exciting pipeline drug, and investors are awaiting potentially exciting data by the end of September.

Via The Motley Fool

VKTX Stock Extends Red-Hot Streak: Insider Scoops Up Shares As Multiple Phase 3 Trials Loom This Year In Obesity Race ↗

March 11, 2026

Viking says it needs only about 5%-10% market share to succeed in the obesity market, despite competition from Eli Lilly and Novo Nordisk.

Via Stocktwits

Performance

YTD	+0.6%	+0.6%
1 Month	+22.9%	+22.9%
3 Month	-1.4%	-1.4%
6 Month	+47.9%	+47.9%
1 Year	+19.4%	+19.4%

More News

The Great Rotation: Russell 2000 Surges as Investors Flee Overstretched Tech Giants

March 10, 2026

Via MarketMinute

Viking CEO Sees Its Obesity Drug Beating Novo's Wegovy In Weight Loss ↗

March 10, 2026

Via Stocktwits

The $1.35 Trillion Wall: Why Small-Caps are Faltering as the S&P 500 Defies Gravity

March 09, 2026

Via MarketMinute

Forget AI Stocks: This Potentially Disruptive Biotech Could Soar By 181%, According to Wall Street ↗

March 09, 2026

Via The Motley Fool

The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026

February 27, 2026

Via Finterra

Viking Therapeutics: The High-Stakes Weight Loss Contender ↗

February 26, 2026

Via MarketBeat

Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. ↗

February 25, 2026

Via The Motley Fool

Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making. ↗

February 23, 2026

Via The Motley Fool

Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial

February 23, 2026

Via MarketMinute

Why Viking Therapeutics Stock Is Up More Than 9% Today ↗

February 23, 2026

Via The Motley Fool

Eli Lilly Surges as Novo Nordisk’s "CagriSema" Stumbles in High-Stakes Obesity Head-to-Head

February 23, 2026

Via MarketMinute

Novo Nordisk Shares Plunge 13% as Next-Gen Weight Loss Drug CagriSema Fails to Topple Eli Lilly in Landmark Trial

February 23, 2026

Via MarketMinute

3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds ↗

February 23, 2026

Via The Motley Fool

2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗

February 19, 2026

Via The Motley Fool

Is Viking Therapeutics Stock Really Going to $125? ↗

February 19, 2026

Via The Motley Fool

The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth

February 17, 2026

Via MarketMinute

2026 Could Be a Big Year for Viking Therapeutics. Time to Buy? ↗

February 17, 2026

Via The Motley Fool

The Great Rotation: Russell 2000 Rockets 18% as Cooling Inflation Sparks Historic Small-Cap Surge

February 13, 2026

Via MarketMinute

Small Caps Roar: Russell 2000 Surges as Cooling Inflation Ignites Rate Cut Hopes

February 13, 2026

Via MarketMinute

VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? ↗

February 12, 2026

Via Stocktwits

Viking Therapeutics Stock Soars: What's Driving The Momentum? ↗

February 12, 2026

Via Benzinga

Nasdaq, S&P 500 Futures Rise, Markets Await Jobless Claims: Why NVDA, META, NKTR, NVCR, AMAT, ASTS Are On Traders' Radar Today ↗

February 12, 2026

Via Stocktwits

Viking (VKTX) Q4 2025 Earnings Call Transcript ↗

February 11, 2026

Via The Motley Fool

Frequently Asked Questions

Is Viking Therapeutics, Inc. - Common Stock publicly traded?

Yes, Viking Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Viking Therapeutics, Inc. - Common Stock trade on?

Viking Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Viking Therapeutics, Inc. - Common Stock?

The ticker symbol for Viking Therapeutics, Inc. - Common Stock is VKTX on the Nasdaq Stock Market

What is the current price of Viking Therapeutics, Inc. - Common Stock?

The current price of Viking Therapeutics, Inc. - Common Stock is 35.63

When was Viking Therapeutics, Inc. - Common Stock last traded?

The last trade of Viking Therapeutics, Inc. - Common Stock was at 03/13/26 04:00 PM ET

What is the market capitalization of Viking Therapeutics, Inc. - Common Stock?

The market capitalization of Viking Therapeutics, Inc. - Common Stock is 3.55B

How many shares of Viking Therapeutics, Inc. - Common Stock are outstanding?

Viking Therapeutics, Inc. - Common Stock has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.